img

Global Pulmonary Arterial Hypertension Treatment Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pulmonary Arterial Hypertension Treatment Market Insights, Forecast to 2034

Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.
Market Analysis and InsightsGlobal Pulmonary Arterial Hypertension Treatment Market
Global Pulmonary Arterial Hypertension Treatment market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Pulmonary Arterial Hypertension Treatment industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Pulmonary Arterial Hypertension Treatment market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Pulmonary Arterial Hypertension Treatment market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


GSK
Eli Lilly and Company
Pfizer Inc
Actelion Inc
United Therapeutic Corporation
SteadyMed Ltd
Gilead Sciences, Inc
Teva Pharmaceuticals Inc
Bayer AG
Segment by Type
Vasodilators
Phosphodiesterase 5 (PDE 5) Inhibitors
Endothelin Receptor Antagonists (ERA)
Soluble Guanylate Cyclase (SGC) Stimulator

Segment by Application


Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Pulmonary Arterial Hypertension Treatment introduction, etc. Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports’s Conclusions of Pulmonary Arterial Hypertension Treatment
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Vasodilators
1.2.3 Phosphodiesterase 5 (PDE 5) Inhibitors
1.2.4 Endothelin Receptor Antagonists (ERA)
1.2.5 Soluble Guanylate Cyclase (SGC) Stimulator
1.3 Market by Application
1.3.1 Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pulmonary Arterial Hypertension Treatment Market Perspective (2018-2029)
2.2 Global Pulmonary Arterial Hypertension Treatment Growth Trends by Region
2.2.1 Pulmonary Arterial Hypertension Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pulmonary Arterial Hypertension Treatment Historic Market Size by Region (2018-2024)
2.2.3 Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Region (2024-2029)
2.3 Pulmonary Arterial Hypertension Treatment Market Dynamics
2.3.1 Pulmonary Arterial Hypertension Treatment Industry Trends
2.3.2 Pulmonary Arterial Hypertension Treatment Market Drivers
2.3.3 Pulmonary Arterial Hypertension Treatment Market Challenges
2.3.4 Pulmonary Arterial Hypertension Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Pulmonary Arterial Hypertension Treatment by Players
3.1.1 Global Pulmonary Arterial Hypertension Treatment Revenue by Players (2018-2024)
3.1.2 Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Players (2018-2024)
3.2 Global Pulmonary Arterial Hypertension Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Pulmonary Arterial Hypertension Treatment, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Pulmonary Arterial Hypertension Treatment Market Concentration Ratio
3.4.1 Global Pulmonary Arterial Hypertension Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension Treatment Revenue in 2022
3.5 Global Key Players of Pulmonary Arterial Hypertension Treatment Head office and Area Served
3.6 Global Key Players of Pulmonary Arterial Hypertension Treatment, Product and Application
3.7 Global Key Players of Pulmonary Arterial Hypertension Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Pulmonary Arterial Hypertension Treatment Breakdown Data by Type
4.1 Global Pulmonary Arterial Hypertension Treatment Historic Market Size by Type (2018-2024)
4.2 Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Type (2024-2029)
5 Pulmonary Arterial Hypertension Treatment Breakdown Data by Application
5.1 Global Pulmonary Arterial Hypertension Treatment Historic Market Size by Application (2018-2024)
5.2 Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Pulmonary Arterial Hypertension Treatment Market Size (2018-2029)
6.2 North America Pulmonary Arterial Hypertension Treatment Market Size by Type
6.2.1 North America Pulmonary Arterial Hypertension Treatment Market Size by Type (2018-2024)
6.2.2 North America Pulmonary Arterial Hypertension Treatment Market Size by Type (2024-2029)
6.2.3 North America Pulmonary Arterial Hypertension Treatment Market Share by Type (2018-2029)
6.3 North America Pulmonary Arterial Hypertension Treatment Market Size by Application
6.3.1 North America Pulmonary Arterial Hypertension Treatment Market Size by Application (2018-2024)
6.3.2 North America Pulmonary Arterial Hypertension Treatment Market Size by Application (2024-2029)
6.3.3 North America Pulmonary Arterial Hypertension Treatment Market Share by Application (2018-2029)
6.4 North America Pulmonary Arterial Hypertension Treatment Market Size by Country
6.4.1 North America Pulmonary Arterial Hypertension Treatment Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2018-2024)
6.4.3 North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Pulmonary Arterial Hypertension Treatment Market Size (2018-2029)
7.2 Europe Pulmonary Arterial Hypertension Treatment Market Size by Type
7.2.1 Europe Pulmonary Arterial Hypertension Treatment Market Size by Type (2018-2024)
7.2.2 Europe Pulmonary Arterial Hypertension Treatment Market Size by Type (2024-2029)
7.2.3 Europe Pulmonary Arterial Hypertension Treatment Market Share by Type (2018-2029)
7.3 Europe Pulmonary Arterial Hypertension Treatment Market Size by Application
7.3.1 Europe Pulmonary Arterial Hypertension Treatment Market Size by Application (2018-2024)
7.3.2 Europe Pulmonary Arterial Hypertension Treatment Market Size by Application (2024-2029)
7.3.3 Europe Pulmonary Arterial Hypertension Treatment Market Share by Application (2018-2029)
7.4 Europe Pulmonary Arterial Hypertension Treatment Market Size by Country
7.4.1 Europe Pulmonary Arterial Hypertension Treatment Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2018-2024)
7.4.3 Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Pulmonary Arterial Hypertension Treatment Market Size (2018-2029)
8.2 China Pulmonary Arterial Hypertension Treatment Market Size by Type
8.2.1 China Pulmonary Arterial Hypertension Treatment Market Size by Type (2018-2024)
8.2.2 China Pulmonary Arterial Hypertension Treatment Market Size by Type (2024-2029)
8.2.3 China Pulmonary Arterial Hypertension Treatment Market Share by Type (2018-2029)
8.3 China Pulmonary Arterial Hypertension Treatment Market Size by Application
8.3.1 China Pulmonary Arterial Hypertension Treatment Market Size by Application (2018-2024)
8.3.2 China Pulmonary Arterial Hypertension Treatment Market Size by Application (2024-2029)
8.3.3 China Pulmonary Arterial Hypertension Treatment Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Pulmonary Arterial Hypertension Treatment Market Size (2018-2029)
9.2 Asia Pulmonary Arterial Hypertension Treatment Market Size by Type
9.2.1 Asia Pulmonary Arterial Hypertension Treatment Market Size by Type (2018-2024)
9.2.2 Asia Pulmonary Arterial Hypertension Treatment Market Size by Type (2024-2029)
9.2.3 Asia Pulmonary Arterial Hypertension Treatment Market Share by Type (2018-2029)
9.3 Asia Pulmonary Arterial Hypertension Treatment Market Size by Application
9.3.1 Asia Pulmonary Arterial Hypertension Treatment Market Size by Application (2018-2024)
9.3.2 Asia Pulmonary Arterial Hypertension Treatment Market Size by Application (2024-2029)
9.3.3 Asia Pulmonary Arterial Hypertension Treatment Market Share by Application (2018-2029)
9.4 Asia Pulmonary Arterial Hypertension Treatment Market Size by Region
9.4.1 Asia Pulmonary Arterial Hypertension Treatment Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Pulmonary Arterial Hypertension Treatment Market Size by Region (2018-2024)
9.4.3 Asia Pulmonary Arterial Hypertension Treatment Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Pulmonary Arterial Hypertension Treatment Introduction
11.1.4 GSK Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.1.5 GSK Recent Developments
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Details
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Introduction
11.2.4 Eli Lilly and Company Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.2.5 Eli Lilly and Company Recent Developments
11.3 Pfizer Inc
11.3.1 Pfizer Inc Company Details
11.3.2 Pfizer Inc Business Overview
11.3.3 Pfizer Inc Pulmonary Arterial Hypertension Treatment Introduction
11.3.4 Pfizer Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.3.5 Pfizer Inc Recent Developments
11.4 Actelion Inc
11.4.1 Actelion Inc Company Details
11.4.2 Actelion Inc Business Overview
11.4.3 Actelion Inc Pulmonary Arterial Hypertension Treatment Introduction
11.4.4 Actelion Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.4.5 Actelion Inc Recent Developments
11.5 United Therapeutic Corporation
11.5.1 United Therapeutic Corporation Company Details
11.5.2 United Therapeutic Corporation Business Overview
11.5.3 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Introduction
11.5.4 United Therapeutic Corporation Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.5.5 United Therapeutic Corporation Recent Developments
11.6 SteadyMed Ltd
11.6.1 SteadyMed Ltd Company Details
11.6.2 SteadyMed Ltd Business Overview
11.6.3 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Introduction
11.6.4 SteadyMed Ltd Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.6.5 SteadyMed Ltd Recent Developments
11.7 Gilead Sciences, Inc
11.7.1 Gilead Sciences, Inc Company Details
11.7.2 Gilead Sciences, Inc Business Overview
11.7.3 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Introduction
11.7.4 Gilead Sciences, Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.7.5 Gilead Sciences, Inc Recent Developments
11.8 Teva Pharmaceuticals Inc
11.8.1 Teva Pharmaceuticals Inc Company Details
11.8.2 Teva Pharmaceuticals Inc Business Overview
11.8.3 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Introduction
11.8.4 Teva Pharmaceuticals Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.8.5 Teva Pharmaceuticals Inc Recent Developments
11.9 Bayer AG
11.9.1 Bayer AG Company Details
11.9.2 Bayer AG Business Overview
11.9.3 Bayer AG Pulmonary Arterial Hypertension Treatment Introduction
11.9.4 Bayer AG Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.9.5 Bayer AG Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Vasodilators
Table 3. Key Players of Phosphodiesterase 5 (PDE 5) Inhibitors
Table 4. Key Players of Endothelin Receptor Antagonists (ERA)
Table 5. Key Players of Soluble Guanylate Cyclase (SGC) Stimulator
Table 6. Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 7. Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Pulmonary Arterial Hypertension Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 9. Global Pulmonary Arterial Hypertension Treatment Market Share by Region (2018-2024)
Table 10. Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Pulmonary Arterial Hypertension Treatment Market Share by Region (2024-2029)
Table 12. Pulmonary Arterial Hypertension Treatment Market Trends
Table 13. Pulmonary Arterial Hypertension Treatment Market Drivers
Table 14. Pulmonary Arterial Hypertension Treatment Market Challenges
Table 15. Pulmonary Arterial Hypertension Treatment Market Restraints
Table 16. Global Pulmonary Arterial Hypertension Treatment Revenue by Players (2018-2024) & (US$ Million)
Table 17. Global Pulmonary Arterial Hypertension Treatment Revenue Share by Players (2018-2024)
Table 18. Global Top Pulmonary Arterial Hypertension Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension Treatment as of 2022)
Table 19. Global Pulmonary Arterial Hypertension Treatment Industry Ranking 2021 VS 2022 VS 2024
Table 20. Global 5 Largest Players Market Share by Pulmonary Arterial Hypertension Treatment Revenue (CR5 and HHI) & (2018-2024)
Table 21. Global Key Players of Pulmonary Arterial Hypertension Treatment, Headquarters and Area Served
Table 22. Global Key Players of Pulmonary Arterial Hypertension Treatment, Product and Application
Table 23. Global Key Players of Pulmonary Arterial Hypertension Treatment, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Pulmonary Arterial Hypertension Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 26. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2018-2024)
Table 27. Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2024-2029)
Table 29. Global Pulmonary Arterial Hypertension Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 30. Global Pulmonary Arterial Hypertension Treatment Revenue Share by Application (2018-2024)
Table 31. Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Pulmonary Arterial Hypertension Treatment Revenue Share by Application (2024-2029)
Table 33. North America Pulmonary Arterial Hypertension Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 34. North America Pulmonary Arterial Hypertension Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 35. North America Pulmonary Arterial Hypertension Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 36. North America Pulmonary Arterial Hypertension Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 37. North America Pulmonary Arterial Hypertension Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 39. North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 40. Europe Pulmonary Arterial Hypertension Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 41. Europe Pulmonary Arterial Hypertension Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 42. Europe Pulmonary Arterial Hypertension Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 43. Europe Pulmonary Arterial Hypertension Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 44. Europe Pulmonary Arterial Hypertension Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 46. Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 47. China Pulmonary Arterial Hypertension Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 48. China Pulmonary Arterial Hypertension Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 49. China Pulmonary Arterial Hypertension Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 50. China Pulmonary Arterial Hypertension Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 51. Asia Pulmonary Arterial Hypertension Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 52. Asia Pulmonary Arterial Hypertension Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 53. Asia Pulmonary Arterial Hypertension Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 54. Asia Pulmonary Arterial Hypertension Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 55. Asia Pulmonary Arterial Hypertension Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 56. Asia Pulmonary Arterial Hypertension Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 57. Asia Pulmonary Arterial Hypertension Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 63. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 65. GSK Company Details
Table 66. GSK Business Overview
Table 67. GSK Pulmonary Arterial Hypertension Treatment Product
Table 68. GSK Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 69. GSK Recent Developments
Table 70. Eli Lilly and Company Company Details
Table 71. Eli Lilly and Company Business Overview
Table 72. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product
Table 73. Eli Lilly and Company Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 74. Eli Lilly and Company Recent Developments
Table 75. Pfizer Inc Company Details
Table 76. Pfizer Inc Business Overview
Table 77. Pfizer Inc Pulmonary Arterial Hypertension Treatment Product
Table 78. Pfizer Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 79. Pfizer Inc Recent Developments
Table 80. Actelion Inc Company Details
Table 81. Actelion Inc Business Overview
Table 82. Actelion Inc Pulmonary Arterial Hypertension Treatment Product
Table 83. Actelion Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 84. Actelion Inc Recent Developments
Table 85. United Therapeutic Corporation Company Details
Table 86. United Therapeutic Corporation Business Overview
Table 87. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product
Table 88. United Therapeutic Corporation Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 89. United Therapeutic Corporation Recent Developments
Table 90. SteadyMed Ltd Company Details
Table 91. SteadyMed Ltd Business Overview
Table 92. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product
Table 93. SteadyMed Ltd Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 94. SteadyMed Ltd Recent Developments
Table 95. Gilead Sciences, Inc Company Details
Table 96. Gilead Sciences, Inc Business Overview
Table 97. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product
Table 98. Gilead Sciences, Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 99. Gilead Sciences, Inc Recent Developments
Table 100. Teva Pharmaceuticals Inc Company Details
Table 101. Teva Pharmaceuticals Inc Business Overview
Table 102. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product
Table 103. Teva Pharmaceuticals Inc Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 104. Teva Pharmaceuticals Inc Recent Developments
Table 105. Bayer AG Company Details
Table 106. Bayer AG Business Overview
Table 107. Bayer AG Pulmonary Arterial Hypertension Treatment Product
Table 108. Bayer AG Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 109. Bayer AG Recent Developments
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Pulmonary Arterial Hypertension Treatment Market Share by Type: 2022 VS 2029
Figure 3. Vasodilators Features
Figure 4. Phosphodiesterase 5 (PDE 5) Inhibitors Features
Figure 5. Endothelin Receptor Antagonists (ERA) Features
Figure 6. Soluble Guanylate Cyclase (SGC) Stimulator Features
Figure 7. Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Pulmonary Arterial Hypertension Treatment Market Share by Application: 2022 VS 2029
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Online Pharmacies Case Studies
Figure 12. Pulmonary Arterial Hypertension Treatment Report Years Considered
Figure 13. Global Pulmonary Arterial Hypertension Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Pulmonary Arterial Hypertension Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Pulmonary Arterial Hypertension Treatment Market Share by Region: 2022 VS 2029
Figure 16. Global Pulmonary Arterial Hypertension Treatment Market Share by Players in 2022
Figure 17. Global Top Pulmonary Arterial Hypertension Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension Treatment as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Pulmonary Arterial Hypertension Treatment Revenue in 2022
Figure 19. North America Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Pulmonary Arterial Hypertension Treatment Market Share by Type (2018-2029)
Figure 21. North America Pulmonary Arterial Hypertension Treatment Market Share by Application (2018-2029)
Figure 22. North America Pulmonary Arterial Hypertension Treatment Market Share by Country (2018-2029)
Figure 23. United States Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Pulmonary Arterial Hypertension Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 26. Europe Pulmonary Arterial Hypertension Treatment Market Share by Type (2018-2029)
Figure 27. Europe Pulmonary Arterial Hypertension Treatment Market Share by Application (2018-2029)
Figure 28. Europe Pulmonary Arterial Hypertension Treatment Market Share by Country (2018-2029)
Figure 29. Germany Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. China Pulmonary Arterial Hypertension Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 36. China Pulmonary Arterial Hypertension Treatment Market Share by Type (2018-2029)
Figure 37. China Pulmonary Arterial Hypertension Treatment Market Share by Application (2018-2029)
Figure 38. Asia Pulmonary Arterial Hypertension Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 39. Asia Pulmonary Arterial Hypertension Treatment Market Share by Type (2018-2029)
Figure 40. Asia Pulmonary Arterial Hypertension Treatment Market Share by Application (2018-2029)
Figure 41. Asia Pulmonary Arterial Hypertension Treatment Market Share by Region (2018-2029)
Figure 42. Japan Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. South Korea Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. China Taiwan Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Southeast Asia Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. India Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Australia Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Share by Type (2018-2029)
Figure 50. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Share by Application (2018-2029)
Figure 51. Middle East, Africa, and Latin America Pulmonary Arterial Hypertension Treatment Market Share by Country (2018-2029)
Figure 52. Brazil Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Mexico Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Turkey Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Israel Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. GCC Countries Pulmonary Arterial Hypertension Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GSK Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 59. Eli Lilly and Company Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 60. Pfizer Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 61. Actelion Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 62. United Therapeutic Corporation Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 63. SteadyMed Ltd Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 64. Gilead Sciences, Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 65. Teva Pharmaceuticals Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 66. Bayer AG Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries